Ebola and rabies protection in one vax?; BiondVax starts Ph2 universal flu vax trial;

Vaccine Research

Researchers have discovered a potential vaccine that would protect against rabies and Ebola in a single jab. According to Thomas Jefferson University scientists, the candidate has showed promising results in mouse trials and could make a significant impact in developing nations where both diseases put people at risk. Item | Piece

Israeli biotech BiondVax is beginning its Phase II universal flu vaccine trial for Multimeric-001. The trial will include 120 patients who are 65 years of age and older and will start in October. BiondVax release

HCM City Pasteur Institute is in the home stretch for its dengue fever vaccine in connection with Sanofi Pasteur. The vaccine will start its final clinical trial in Vietnam next month. Item

Vaccine has published the results of Emergent BioSolutions' ($EBS) Phase Ia anthrax vaccine trial, noting the good responses from BioThrax with 1 mg of CPG 7909 in the 69-person trial. Emergent release

Scientists have found a link between a bovine viral diarrhea virus and bleeding calf syndrome, which causes low blood cell counts and bone marrow depletion in newborn calves. The study was published in Veterinary Research. Release

Vaccine Market

Selecta Biosciences has garnered a malaria vaccine subcontract from Science Applications International with support from NIAID. In addition, the company has named Takashi Kei Kishimoto as its new chief scientific officer. Article

And Finally... Russia's chief sanitary inspector Gennady Onishchenko believes his country is being cast aside by UNICEF's polio vaccination efforts, and that possibility is dangerous for the nation's biotech industry. Item

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.